Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00056537
Status:
COMPLETED
Last Update Posted:
2014-08-27
First Post:
2003-03-16
Brief Title:
ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer Renal Clear Cell Carcinoma or Pancreatic Cancer
Sponsor:
Active Biotech AB
Organization:
Active Biotech AB
Study Overview
Official Title:
An Open-Label Phase I Repeat Dose-Escalation Study of ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer Renal Clear Cell Carcinoma or Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The drug ABR-217620 is a combination of two proteins one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the bodys normal immune system In animals this results in an accumulation of white blood cells in the cancer that can fight the cancer This study will test how much of the drug can be given to patients with non-small cell lung cancer renal clear cell carcinoma or pancreatic cancer without causing unacceptable side effects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None